**Global Vaccine Action Plan (GVAP) and Regional framework indicators**

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Status</th>
<th>Source of data for NIP target</th>
<th>NIP target &lt; 1 year (surviving infants)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polio-free status sustained</td>
<td>Yes</td>
<td>* United Nations World Population Prospects: The 2015 Revision</td>
<td></td>
</tr>
<tr>
<td>Country achieved MNT elimination</td>
<td>No</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country verified for measles elimination</td>
<td>No</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Seroprevalence of chronic hepatitis B infection (HBsAg) reduced to &lt; 1% in 5 year olds by 2017</td>
<td>No data</td>
<td></td>
<td></td>
</tr>
<tr>
<td>At least one new or underutilized vaccine introduced since 2010*</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DTP3 national immunization coverage ≥ 95% by 2020</td>
<td>54.8%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DTP3 coverage ≥ 90% in at least 90% of districts (proportion of districts with ≥ 90% coverage)</td>
<td>No (4.7%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sustained DTP3 coverage ≥ 95% for three or more years</td>
<td>No</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DTP dropout rate &lt; 5%</td>
<td>14.51%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>* New or underutilized vaccines include Hib, HPV, PCV and RV. IPV and JE are not counted. Otherwise, &quot;Yes (specified)&quot; is indicated to account for other vaccines.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Population**

<table>
<thead>
<tr>
<th>Year</th>
<th>JRF</th>
<th>UN*</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>101,771,950</td>
<td>100,699,395</td>
</tr>
<tr>
<td>2012</td>
<td>2,747,843</td>
<td>2,348,789</td>
</tr>
<tr>
<td>2013</td>
<td>2,679,147</td>
<td>2,290,022</td>
</tr>
</tbody>
</table>

* World Bank Open Data

**Finance**

<table>
<thead>
<tr>
<th>Year</th>
<th>Gross national income per capita* (US $)</th>
<th>$ 3540</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>100,000</td>
<td></td>
</tr>
<tr>
<td>2012</td>
<td>1,000,000</td>
<td></td>
</tr>
<tr>
<td>2013</td>
<td>2,000,000</td>
<td></td>
</tr>
</tbody>
</table>

* World Bank Open Data

**Reported cases of selected vaccine preventable diseases**

<table>
<thead>
<tr>
<th>Year</th>
<th>Acute flaccid paralysis (AFP)</th>
<th>Measles</th>
<th>Rubella</th>
<th>Congenital rubella syndrome (CRS)</th>
<th>Neonatal tetanus</th>
<th>Total tetanus</th>
<th>Diphtheria</th>
<th>Pertussis</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>0.9</td>
<td>6538</td>
<td>926</td>
<td>166</td>
<td>1537</td>
<td>1.6</td>
<td>0</td>
<td>0.0</td>
</tr>
<tr>
<td>2012</td>
<td>1.1</td>
<td>1536</td>
<td>100</td>
<td>131</td>
<td>839</td>
<td>0.8</td>
<td>0</td>
<td>0.0</td>
</tr>
<tr>
<td>2013</td>
<td>0.7</td>
<td>2,920</td>
<td>254</td>
<td>77</td>
<td>1,069</td>
<td>1.1</td>
<td>6</td>
<td>0.0</td>
</tr>
<tr>
<td>2014</td>
<td>0.7</td>
<td>58,848</td>
<td>264</td>
<td>92</td>
<td>880</td>
<td>0.9</td>
<td>9</td>
<td>0.0</td>
</tr>
</tbody>
</table>

**Invasive bacterial disease, rotavirus and japanese encephalitis**

<table>
<thead>
<tr>
<th>Year</th>
<th>Surveillance system type</th>
<th>Confirmed cases</th>
<th>Surveillance system type</th>
<th>Confirmed cases</th>
<th>Surveillance system type</th>
<th>Confirmed cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>Sentinel (7 sites)</td>
<td>325</td>
<td>Sentinel (4 sites)</td>
<td>24</td>
<td>Nationwide</td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td>Sentinel (7 sites)</td>
<td>725</td>
<td>Sentinel (9 sites)</td>
<td>69</td>
<td>Sentinel (9 sites)</td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td>Sentinel (7 sites)</td>
<td>826</td>
<td>Sentinel (9 sites)</td>
<td>61</td>
<td>Sentinel (9 sites)</td>
<td></td>
</tr>
</tbody>
</table>

**Confirmed measles cases by month of onset 2011–2015**

**Confirmed measles cases by age group and vaccination status, 2014–2015**
Philippines, 2015

Immunization schedule

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>B</th>
<th>DTP-Hib-HepB</th>
<th>W6, W10, W14</th>
<th>Td</th>
<th>Y6, Y10</th>
<th>Measles</th>
<th>M9</th>
<th>HPV</th>
<th>Y9-10, Y9-10</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCG</td>
<td>B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HepB</td>
<td>B</td>
<td></td>
<td>W6, W10, W14</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IPV</td>
<td>W14</td>
<td>Pneumo_conj</td>
<td>W6, W10, W14</td>
<td></td>
<td>Pneumo_ps</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B=birth, W=week, M=month, Y=year

NIP priority needs

1. Ensure availability and timely distribution of vaccines
2. Strengthening the routine immunization through reaching every purok strategy
3. Introduction of new and under-utilized vaccines

Immunization schedule

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>B</th>
<th>DTP-Hib-HepB</th>
<th>W6, W10, W14</th>
<th>Td</th>
<th>Y6, Y10</th>
<th>Measles</th>
<th>M9</th>
<th>HPV</th>
<th>Y9-10, Y9-10</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCG</td>
<td>B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HepB</td>
<td>B</td>
<td></td>
<td>W6, W10, W14</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IPV</td>
<td>W14</td>
<td>Pneumo_conj</td>
<td>W6, W10, W14</td>
<td></td>
<td>Pneumo_ps</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B=birth, W=week, M=month, Y=year

Planning

Multi-year plan (MYP) Yes (2015-2019)
Annual workplan for immunization activities Yes
Updated wild poliovirus importation and cVDPV response plan Yes

Safe immunization

% districts using auto-disable syringes Yes
Number of AEFI 134
Injection safety policy implemented Yes
Disposal methods Burial
Injection safety review Yes (National)

Delivery of immunization services

% of population served by outreach
No. (%) of districts with DTP3 coverage < 80% 166 (86%)
No. (%) of districts with DTP3 coverage ≥ 90% 9 (5%)
No. (%) of districts with MCV1 coverage < 80% 70 (37%)
No. (%) of districts with MCV1 coverage ≥ 90% 58 (30%)
No. (%) of districts with DTP drop-out > 10% 98 (51%)
No. (%) of districts with DTP–MCV1 drop-out > 10% 6 (3%)

School-based immunization

Is there a school entry requirement? Yes
If no, do schools check immunization status at enrolment? MCV, HepB, MMR
At what school level/year? Pre-school
Is routine vaccination given at school? Yes
Which vaccination? MR, TD
If yes, is this part of a comprehensive school-health program that delivers other health interventions? Yes

Measles and rubella elimination

Confirmed measles case rate* (per 1 million population) 6.8
Year of MCV1 introduction 1983
Confirmed rubella case rate* (per 1 million population) 1.5
Year of MCV2 introduction 2010
Discarded as non-measles case rate* (Target: ≥ 2 per 100 000 population) 1.4
Year of RCV introduction 2010
% suspected cases with adequate specimens* (Target: ≥ 80%) 69.7%
Surveillance conducted for CRS No
Imported measles cases* 0
Antigens, year and target population of last SIA MR - 2014 (9-59 mos)
Measles cases with unknown source of infection* 688
Number vaccinated (SIA coverage) 10 402 489 (91%)

* Data from measles monthly country reports to WHO

Surveys

Coverage survey
Serosurvey
Most recent (year) 2015
Year MCV1 introduction 1983
Type Lot quality assessment
Geographical representativeness Subnational
Result The Philippines is likely to eliminate MNT.

Hepatitis B control

Year HepB3 vaccine introduced nationwide 1991 Systems to deliver HepB vaccine birth dose Hospitals, health centers, home
Year HepB birth dose introduced 2007 HBsAg results assessed for blood donors No
HepB birth dose (within 24 hours) coverage 51.4% Policy for screening of pregnant women No
HepB birth dose (within and after 24 hours) coverage 57% Policy to vaccinate health care workers Yes

Reported immunization coverage, 2006–2015